Comorbidity and age affect treatment policy for cervical cancer: a population-based study in the south of the Netherlands, 1995-2004

MNM (Madelon) van der Aa, S Siesling, RFPM Kruitwagen, MLM Lybeert, Jan Willem Coebergh, Maryska Heijnen

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)

Abstract

Objective. The aim of this study was to estimate the effects of age and comorbidity on the choice of treatment modalities and prognosis for patients with cervical cancer. Methods. All patients with cervical cancer newly diagnosed between 1995 and 2004 (n = 775) were selected from the population-based Eindhoven Cancer Registry. Time trends in treatment modalities and differences in treatment between older and younger patients, and those with and without comorbidity were evaluated. Results. Older patients with FIGO Stages IB-IIA, elderly and those with comorbidity underwent less surgery. In multivariate survival analysis, age had independent prognostic value. For patients with FIGO Stages 1132, IIB-IVA, age affected the choice of chemoradiation significantly. According to multivariate survival analysis, comorbidity and FIGO stage were independent prognostic factors. Conclusion. Older patients with cervical cancer and those with comorbidity were treated less aggressively. Because of the ever-increasing role of comorbidity in clinical decision-making for increasingly older patients in the near future, development of age-specific guidelines incorporating levels and management of specific comorbidity seems warranted.
Original languageUndefined/Unknown
Pages (from-to)493-498
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Volume29
Issue number5
Publication statusPublished - 2008

Cite this